PT-141 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
PT-141 (Bremelanotide) is a Melanocortin receptor agonist researched for increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement. Common dosages range from 1.75 mg per dose (FDA-approved) administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month. Below are the most frequently asked questions.
Frequently Asked Questions About PT-141
What is PT-141?
PT-141 (Bremelanotide) is a Melanocortin receptor agonist. Synthetic α-MSH analog targeting MC1R and MC4R for sexual desire modulation. It is researched for increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement.
What is the recommended PT-141 dosage?
Common dosages range from 1.75 mg per dose (FDA-approved), administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month via subcutaneous self-injection. Cycles typically run on-demand acute dosing; no continuous cycle required.
What are the side effects of PT-141?
Nausea (40% incidence, especially first injection), flushing (20%), injection site reactions (13%), headache (11%). Transient blood pressure increases (2-3 mmHg average). Contraindicated in uncontrolled hypertension.
Is PT-141 legal?
FDA-approved (2019) as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Prescription medication. Off-label use for males by some providers.
What is the half-life of PT-141?
The half-life of PT-141 is peak effects 15-30 minutes post-injection, which determines the on-demand, 45 minutes before anticipated activity; maximum 8 doses per month dosing schedule.
How do you reconstitute PT-141?
Add bacteriostatic water to the lyophilized PT-141 vial. Let the water run down the side — never spray on the powder. Swirl gently. Use our peptide calculator for exact amounts.
Can you stack PT-141 with other peptides?
Works through a unique mechanism distinct from PDE5 inhibitors; not typically combined with other sexual enhancement agents.
Where can you buy PT-141?
PT-141 is available as a research chemical from vetted suppliers with third-party COA testing.
How long does it take PT-141 to work?
Initial effects may be noticed within 1-2 weeks, with more significant results typically appearing by weeks 4-8 of a on-demand acute dosing; no continuous cycle required cycle.
What makes PT-141 unique?
One of the few FDA-approved peptide therapies and the only medication targeting sexual desire through melanocortin brain pathways rather than vascular mechanisms — treats desire itself, not just physical function.
Complete Guide
PT-141 (Bremelanotide): Research
Related Reading
- PT-141 Dosage Guide
- PT-141 Benefits
- PT-141 Side Effects
- PT-141 Stacking Guide
- PT-141 Cycle Guide
- PT-141 Research
Calculate Your PT-141 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PT-141.
Open Calculator →Research-Grade Sourcing
If you're going to research PT-141, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is a Melanocortin receptor agonist. Synthetic α-MSH analog targeting MC1R and MC4R for sexual desire modulation. It is researched for increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement.
What is the recommended PT-141 dosage?
Common dosages: 1.75 mg per dose (FDA-approved) administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month via subcutaneous self-injection. Cycle length: on-demand acute dosing; no continuous cycle required. Half-life: peak effects 15-30 minutes post-injection. Use our peptide calculator for exact reconstitution math.
What are the side effects of PT-141?
Nausea (40% incidence, especially first injection), flushing (20%), injection site reactions (13%), headache (11%). Transient blood pressure increases (2-3 mmHg average). Contraindicated in uncontrolled hypertension.
Is PT-141 safe?
PT-141 has shown a preliminary safety profile in research. FDA-approved (2019) as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Prescription medication. Off-label use for males by some providers. All research should follow appropriate safety protocols.